Results 161 to 170 of about 453,251 (315)

Development of Potent and Selective Janus Kinase 2/3 Directing PG-PROTACs. [PDF]

ACS Med Chem Lett, 2022
Alcock LJ, Chang Y, Jarusiewicz JA, Actis M, Nithianantham S, Mayasundari A, Min J, Maxwell D, Hunt J, Smart B, Yang JJ, Nishiguchi G, Fischer M, Mullighan CG, Rankovic Z.   +14 more
europepmc   +1 more source

The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia [PDF]

, 2018
Choi, Jaebok, DiPersio, John F, Schroeder, Mark A, Staser, Karl   +3 more
core   +2 more sources

Dexmedetomidine Suppresses Glutamate-Stimulated Neuronal Injury Via MicroRNA-433/Janus Kinase 2/Signal Transducer and Activator of Transcription 3 Pathway. [PDF]

Iran J Biotechnol, 2023
Zhao L, Huang J, Wu Z, Fu G.
europepmc   +1 more source

LncRNA NORAD Enhances Inflammatory Injury in Sepsis‐Associated Acute Lung Damage Through miR‐150‐5p/STAT1‐Dependent NF‐κB Activation

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Acute lung injury (ALI) is a severe complication of sepsis, yet the role of lncRNA NORAD in its pathogenesis remains unclear. Using LPS‐stimulated BEAS‐2B and HBEC3‐KT cells as well as cecal ligation and puncture (CLP)‐induced ALI models in C57BL/6 mice, we found that NORAD expression was markedly upregulated and promoted cell injury ...
Han Liu, Xi‐Xi Chen, Gui‐Hua Wei, Feng Li, Hai‐Yan Zong   +4 more
wiley   +1 more source

A Case Report of Large Bilateral Pulmonary Embolism in a Patient With Janus Kinase 2 (JAK2) Positive Mutation. [PDF]

Cureus, 2022
Khan Z, Besis G.
europepmc   +1 more source

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.

The Lancet Haematology, 2017
C. Harrison, N. Schaap, A. Vannucchi, J. Kiladjian, R. Tiu, P. Zachée, E. Jourdan, E. Winton, R. Silver, H. Schouten, F. Passamonti, S. Zweegman, M. Talpaz, J. Lager, Z. Shun, R. Mesa   +15 more
semanticscholar   +1 more source

Investigation of the Mechanism of Cinnamaldehyde in Irritable Bowel Syndrome Based via Network Pharmacology, Molecular Docking, and Animal Experiments

Pediatric Discovery, EarlyView.
Through network pharmacology and molecular docking, it has been discovered that CA can target MAOB, among other proteins, to exert a therapeutic effect in IBS. In vivo, CA lowered visceral hypersensitivity, anxiety and depression‐like behaviors, and fecal water content, highlighting its therapeutic potential for IBS via anti‐inflammatory pathways ...
Qingyang Yu, Boqing Xu, Chunfang Dai, Yayan Pang, Zhifang Dong   +4 more
wiley   +1 more source

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. [PDF]

Br J Haematol, 2022
Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Zhang J, Sy O, Mesa RA.   +11 more
europepmc   +1 more source

Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Portal Hypertension &Cirrhosis, EarlyView.
MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang, Zhenyu Liu, Jun Lin, Weijing Zhang, Xianzhi Liu, Tong Zhang   +5 more
wiley   +1 more source

Essential Thrombocythemia Due to Janus Kinase 2 Mutation Unmasked After Splenectomy. [PDF]

Cureus, 2021
Khanduri A, Gupta R, Gupta J, Ammar H.
europepmc   +1 more source